PCSK9 inhibitor safe for cognitive function, even at very low cholesterol levels

ACC 2017 Dr. Robert Giugliano presented the EBBINGHAUS trial, testing the cognitive function of almost 2000 patients from the FOURIER trial. There was no difference between the groups with the PCSK9-inhibitor and placebo, even at very low cholesterol levels.

Educational information

The EBBINGHAUS trial was presented during Late-Breaking Clinical Trial Session 2 (March 18), ACC 2017, Washington DC, USA

Recorded at ACC 2017, Washington DC, USA.

Disclosures

Dr. Robert Giugliano (member Executive Committee, EBBINGHAUS and FOURIER clinical trials program; Senior Investigator, TIMI Study Group, Staff Physician, Cardiovascular Division, Brigham and Women’s Hospital. Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA)